<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02177305</url>
  </required_header>
  <id_info>
    <org_study_id>205.138</org_study_id>
    <nct_id>NCT02177305</nct_id>
  </id_info>
  <brief_title>Dose Tolerance Study After Ocular Administration of Tiotropium in Healthy Male Volunteers</brief_title>
  <official_title>A Single Increasing Dose Tolerance Study After Ocular Administration of Tiotropium (Single Doses: 0.02 - 0.4 mcg) in Healthy Male Volunteers (Randomised, Placebo-controlled, Double-blind, Parallel Groups).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Safety and tolerability after ocular administration
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <primary_completion_date type="Actual">December 1998</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pupil diameter</measure>
    <time_frame>baseline, after 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pupillary reflex</measure>
    <time_frame>baseline, after 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in intraocular pressure</measure>
    <time_frame>baseline, after 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in accommodation</measure>
    <time_frame>baseline, after 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure</measure>
    <time_frame>on Day 1 before and 24 hours after treatment and within 8 days after treatment day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pulse rate</measure>
    <time_frame>on Day 1 before and 24 hours after treatment and within 8 days after treatment day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 12-lead ECG</measure>
    <time_frame>on Day 1 before and 24 hours after treatment and within 8 days after treatment day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in standard laboratory examinations</measure>
    <time_frame>Baseline and within 8 days after treatment day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>until 8 days after treatment day</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tiotropium dose group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.02 mcg tiotropium solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium dose group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.04 mcg tiotropium solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium dose group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.08 mcg tiotropium solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium dose group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.16 mcg tiotropium solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium dose group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.28 mcg tiotropium solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium dose group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.40 mcg tiotropium solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.02 mcg tiotropium solution</intervention_name>
    <arm_group_label>Tiotropium dose group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.04 mcg tiotropium solution</intervention_name>
    <arm_group_label>Tiotropium dose group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.08 mcg tiotropium solution</intervention_name>
    <arm_group_label>Tiotropium dose group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.16 mcg tiotropium solution</intervention_name>
    <arm_group_label>Tiotropium dose group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.28 mcg tiotropium solution</intervention_name>
    <arm_group_label>Tiotropium dose group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.40 mcg tiotropium solution</intervention_name>
    <arm_group_label>Tiotropium dose group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo solution</intervention_name>
    <arm_group_label>Tiotropium dose group 1</arm_group_label>
    <arm_group_label>Tiotropium dose group 2</arm_group_label>
    <arm_group_label>Tiotropium dose group 3</arm_group_label>
    <arm_group_label>Tiotropium dose group 4</arm_group_label>
    <arm_group_label>Tiotropium dose group 5</arm_group_label>
    <arm_group_label>Tiotropium dose group 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males

          -  Age range from 21 to 50 years

          -  Within ± 20% of normal weight (Broca-Index)

          -  Written informed consent given

        Exclusion Criteria:

          -  Results of the medical examinations or laboratory tests are judged by the clinical
             investigator to differ significantly from normal clinical values

          -  Volunteers with known gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunological or hormonal disorders

          -  Volunteers with disease of the central nervous system (such as epilepsy) or with
             psychiatric disorders

          -  Volunteers with known history of orthostatic hypotension, fainting spells or blackouts

          -  Volunteers with chronic or relevant acute infections

          -  Volunteers with history of allergy/ hypersensitivity (including drug allergy)

          -  Volunteers with known eye diseases (incl. glaucoma), with hyperopia (&gt; 3 diopters) or
             with contact lenses

          -  Volunteers with intraocular pressure &gt; 22 mmHg

          -  Volunteers with predisposition to narrow-angle glaucoma

          -  Volunteers with disturbed micturition

          -  Volunteers who have taken a drug with a long half-life (≥ 24 hours) within ten
             half-lives of the respective drug before enrolment in the study

          -  Volunteers who received any other drugs which might influence the results of the trial
             during the week previous the start of the study

          -  Volunteers who have participated in another study with an investigational drug within
             the last two months preceding this study

          -  Volunteers who smoke (&gt; 10 cigarettes or 3 cigars or 3 pipes/day)

          -  Volunteers who are not able to refrain from smoking on study day

          -  Volunteers who drink more than 40 g of alcohol per day

          -  Volunteers who are dependent on drugs

          -  Volunteers who have donated blood (≥ 100 ml) within the last four weeks

          -  Volunteers who participated in excessive physical activities (e.g. competitive sports)
             within the last week before the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

